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Rift Valley Fever  
Infectious Enzootic Hepatitis of 
Sheep and Cattle  
 
Last Updated: January 2015  
 
 
 
Importance  
Rift Valley fever (RVF) is a zoonotic viral disease that can affect a variety of 
species, including ruminants and camels, causing high mortality in young animals 
and/or abortions in adults. The RVF virus is endemic mainly in subSaharan Africa, 
but it has also been seen in North Africa, and may have become established in Egypt. 
There are concerns that this virus might be spreading, after outbreaks were reported in 
Saudi Arabia and Yemen in 2000. Rift Valley fever tends to occur in periodic 
epidemics, which typically occur after heavy rainfalls and may be devastating to 
domesticated livestock. These outbreaks are thought to begin when dormant, infected 
mosquito eggs hatch in flooded areas. However, the epidemiology of Rift Valley 
fever is incompletely understood, and low levels of infection have now been 
identified during interepidemic periods.  
Rift Valley fever outbreaks in domesticated animals are often accompanied by 
human disease. Many human cases are caused by occupational exposure to blood and 
tissues from infected animals, but mosquito-borne transmission can also occur. The 
most common form of the disease is a self-limiting, flu-like illness. Complications in 
a minority of cases include ocular disease, neurological signs, kidney dysfunction and 
a life-threatening hemorrhagic syndrome with hepatic dysfunction. Although overall 
case fatality rates are thought to be low (≤ 2%), there may be very large number of 
cases during some epidemics, resulting in hundreds of serious cases and significant 
numbers of deaths.  
Etiology  
Rift Valley fever results from infection by the Rift Valley fever virus, an RNA 
virus in the genus Phlebovirus in the family Bunyaviridae. There are several genetic 
lineages of this virus, some of which may co-circulate, in endemic regions. Some 
viral isolates differ in virulence in laboratory rodents and possibly other species. 
Species Affected  
Rift Valley fever can affect many species of animals including sheep, cattle, 
goats, African buffalo (Syncerus caffer), water buffalo (Bubalus bubalis), camels, 
some species of monkeys, and a number of rodents (various wild African rodents, rats 
[Rattus rattus], nonnative gray squirrels [Sciurus carolinensis] and laboratory rodents 
including hamsters, gerbils, rats and mice, but not guinea pigs). Severe disease can be 
seen in newborn puppies and kittens, although adult dogs and cats seem to be 
unaffected. Some experimentally infected ferrets developed febrile reactions. Limited 
information suggests that some wild ruminants (in addition to African buffalo) are 
also susceptible to disease.  
Sheep, goats and cattle are thought to be the primary amplifying hosts among 
domesticated animals, although other species such as camels could also be involved. 
The role of wildlife is still being investigated, but some animals might amplify the 
virus, or help maintain it during interepidemic periods. In addition to African buffalo, 
serological evidence of infection has been reported in other wild ruminants (e.g., 
Thomson's gazelle [Gazella thomsonii], lesser kudu [Tragelaphus strepsiceros], 
impala [Aepyceros melampus] and waterbuck [Kobus ellipsiprymnus]), as well as in 
black rhinocerus (Diceros bicornis), African elephant (Loxodonta africana) and 
warthog (Phacochoerus aethiopicus). Some wild species, such as giraffe, seem to 
become infected mainly during outbreaks in domesticated animals, and may be 
unlikely to maintain the virus. Wild rodents have been proposed as possible hosts for 
RVF virus, but their role (if any) is currently uncertain. There is also evidence for 
infection in other species including bats. Birds do not become infected in laboratory 
experiments, and surveillance has not detected any evidence of infection in nature. 
Zoonotic potential 
Humans are susceptible to infection with Rift Valley fever virus, and can develop 
clinical signs. The viremia may be sufficient to infect mosquitoes. 
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Geographic Distribution  
The Rift Valley fever virus is endemic in Africa south 
of the Sahara desert. Although outbreaks are most common 
in southern and eastern Africa, they also occur in other 
regions. Outbreaks or infections have been reported 
sporadically in Egypt and various islands off the coast of 
Africa (e.g., Madagascar, Mayotte), and a major outbreak 
occurred on the Arabian Peninsula (Saudi Arabia and 
Yemen) in 2000-2001. Rift Valley fever might have 
become endemic in some of these regions, including Egypt; 
however, this can be difficult to determine, both because 
the virus is not necessarily found during interepidemic 
periods, and because some reported infections may result 
from illegal animal importation.  
Transmission  
Rift Valley fever is transmitted by mosquitoes, which 
act as biological vectors. This virus has been detected in 
many genera of mosquitoes in endemic regions; however, 
laboratory experiments suggest that some of these species 
are not competent vectors for transmission. At present, the 
major hosts appear to be members of the genera Aedes, 
Culex and Anopheles. Other biting insects might also be 
able to transmit this virus from viremic animals, although 
their role (if any) in nature is still uncertain. Potential 
mechanical and/or biological vectors include stable flies 
(Stomoxys spp.), tsetse flies (Glossina morsitans), sandflies 
(Lutzomyia longipalpis), biting midges (Culicoides 
variipennis), blackflies and ticks. RVF virus was not 
detected in approximately 1000 ticks collected from 
livestock during one recent outbreak.  
The mechanisms that maintain RVF virus in nature and 
cause it to emerge in epidemic form are incompletely 
understood, and might differ between areas. Transmission 
cycles are best understood in savannah regions, where the 
virus is thought to survive between outbreaks in the dried 
eggs of Aedes mosquitoes found in shallow depressions in 
the soil (dambos). Infected mosquitoes are thought to hatch 
when the dambos fill after heavy rainfall, and initiate 
transmission cycles involving additional mosquito species, 
and animals that act as amplifying hosts. The vertebrate 
amplifying hosts are thought to be critical in propagating 
epidemics. Virus transmission has also been demonstrated 
at low levels in livestock, wildlife and humans during 
interepidemic periods. Infection cycles in some other 
climates, such as forested regions, are poorly understood 
and might differ from this pattern. 
RVF virus can be transmitted in utero to the fetus of 
ruminants, camels and other species. This virus may also 
infect other animals exposed to abortion or birth products, 
which contain large amounts of virus; however, the 
importance of this route in propagating epizootics is 
controversial. Although RVF virus can enter the body 
through mucous membranes, and might occur in milk, one 
attempt to inoculate puppies, kittens and lambs with virus-
spiked milk was unsuccessful. Virus shedding in secretions 
and excretions from infected ruminants is poorly 
understood, although it is not thought to be important in 
spreading Rift Valley fever. Some studies have, 
nevertheless, detected small amounts of virus in oral fluids 
and nasal discharge, as well as in semen, and sentinel sheep 
were infected by unknown route(s) during two laboratory 
experiments. There was evidence for horizontal 
transmission during experiments in cats and dogs, and virus 
was detected in the saliva of puppies. RVF virus has not 
been reported in the urine or feces of any species except 
when these excretions are contaminated by blood.   
Humans can acquire RVF virus by direct contact with 
infected tissues, contact with aerosolized viruses generated 
in laboratories or during slaughter, or from mosquitoes. The 
relative importance of mosquito-borne exposure and 
exposure to infected animal tissues continues to be debated. 
Drinking raw (unpasteurized) milk is a significant risk 
factor for human infection, although definitive proof for 
this route is lacking. Vertical transmission to human infants 
has been demonstrated in at least two cases. Person-to-
person transmission does not seem to occur, but the blood 
and tissues of patients might be sources of exposure for 
medical personnel.  
In vitro experiments suggest that RVF virus can persist 
for a few days in some protein-rich environments such as 
tissues. In a neutral or alkaline pH, mixed with serum or 
other proteins, the virus may survive for as long as 4 
months at 4°C (40°F) and 8 years below 0°C (32°F). It is 
quickly destroyed by pH changes in decomposing 
carcasses. Under optimal conditions, RVF virus remained 
viable in aerosols for more than an hour at 25°C (77°F).  
Disinfection  
The Rift Valley fever virus is susceptible to low pH (≤ 
6.2), lipid solvents and detergents, and solutions of sodium 
or calcium hypochlorite with residual chlorine content 
greater than 5000 ppm.  
Infections in Animals  
Incubation Period  
The incubation period in sheep, goats and cattle is 
thought to be approximately 1-3 days, based on laboratory 
experiments. Young ruminants and puppies can develop 
clinical signs as early as 12 hours after inoculation.  
Clinical Signs  
In endemic regions, epidemics of Rift Valley fever are 
characterized by high mortality rates in newborn animals 
and abortions in adults. Between epidemics, this virus can 
circulate without apparent clinical signs in susceptible 
species, or there might be sporadic abortions that could be 
confused with other diseases. 
Rift Valley fever is usually most severe in young 
animals. Nonspecific signs of fever, anorexia, weakness and 
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lymphadenopathy are common in lambs. Hemorrhagic or 
fetid diarrhea, melena, regurgitation, signs of abdominal 
pain, a serosanguineous or bloodstained mucopurulent nasal 
discharge and elevated respiratory rate may also be seen. 
Very young lambs and kids with clinical signs rarely 
survive longer than a few days, and often die with 24 hours. 
Older lambs and kids may die acutely or peracutely, recover 
from the illness, or become infected with few or no clinical 
signs. Similar signs have been reported in young calves, 
although some sources have reported that icterus is more 
likely, and survival rates appear to be higher.  
Abortions, apparently unrelated to the gestation period, 
are the most characteristic sign in adult sheep, goats and 
cattle. There are also reports of abortions in wild ruminants 
including African buffalo, a waterbuck (Kobus 
ellipsiprymnus), a springbuck (most likely Antidorcas 
marsupialis) and a blesbuck (probably Damaliscus dorcas). 
Some pregnant animals have few or no clinical signs other 
than abortion, while others become ill or die. Experimental 
infections in nonpregnant older lambs and adult sheep 
suggest that some animals may have may minimal clinical 
signs (e.g., fever in some animals, slight lethargy), while 
others may have a more severe illness with fever, depression, 
diarrhea, nasal discharge, and neurological signs in some 
cases. Ocular signs (corneal opacity/ edema and erosions, and 
anterior uveitis) occurred 8-9 days after inoculation in some 
minimally affected animals. Hemorrhagic diarrhea has been 
seen in both naturally and experimentally infected sheep, and 
may be more severe in some breeds. A hemorrhagic 
syndrome reported in 7-11-month-old, experimentally 
infected Yansaka sheep (an indigenous Nigerian breed) was 
characterized by petechiae and ecchymoses on mucous 
membranes and unhaired skin, severe respiratory distress 
with epistaxis, severe bloody diarrhea and conjunctival 
hemorrhage. Infections are often subclinical in adult cattle, 
but some animals can have a few days of fever, anorexia, 
weakness, excessive salivation, lacrimation, nasal discharge, 
bloody or fetid diarrhea, and decreased milk production. 
In the past, camels were thought to abort but not 
become ill; however, clinical signs reported during a recent 
outbreak included sudden death or an acute syndrome 
characterized by fever, neurological signs (e.g., ataxia), 
expiratory wheeze, ventral positional dyspnea, edema at the 
base of the neck, icterus, blood-tinged nasal discharge, 
hemorrhages on the oral mucosa and abortions. Camels that 
developed hemorrhagic signs usually died within a few 
days. Severe conjunctivitis and blindness occurred in some 
animals. Foot lesions were also documented in the outbreak 
report, but whether they were caused by Rift Valley fever 
seems uncertain. 
Descriptions of illnesses in other species are based 
mainly on laboratory infections. Some wild or laboratory 
rodents, including rats, mice and hamsters, have nonspecific 
signs (e.g., weight loss, fever) of varying severity, with 
neurological signs and deaths in some cases. Kittens 3 
weeks of age and younger developed neurological signs of 
ataxia and paddling, and many died soon afterward. Some 
very young puppies (≤ 1 week of age) also had neurological 
signs, while other pups of this age died rapidly with few or 
no clinical signs. Adult cats, puppies 2 weeks of age and 
older, and adult dogs appear to be unaffected (with the 
possible exception of reduced fertility in female dogs), 
while a fever was reported in experimentally infected 
ferrets. RVF virus can cause nonspecific signs of illness 
(fever, anorexia, depression), neurological signs, or 
hemorrhagic signs (petechiae, ecchymoses and bleeding 
from the nose, gums or venipuncture sites) in some species 
of nonhuman primates, while some other species seem to be 
unaffected or minimally affected. 
Post Mortem Lesions      Click to view images 
The most consistent lesion in all species is hepatic 
necrosis, which tends to be more extensive and severe in 
younger animals. In aborted fetuses and newborn lambs, the 
liver may be very large, yellowish-brown to dark reddish-
brown, soft and friable, with irregular patches of 
congestion. Multiple gray to white necrotic foci are usually 
present, but may not be grossly visible. The liver lesions are 
often less severe and more localized in calves and adult 
animals, and may consist of numerous pinpoint reddish to 
grayish-white necrotic foci. The walls of the gallbladder 
may be edematous, and can contain visible hemorrhages. 
Hepatic necrosis is also the most prominent and consistent 
microscopic lesion, and eosinophilic oval or rod-shaped 
intranuclear inclusion bodies may be found in the liver in 
up to 50% of cases. 
Additional gross lesions may include jaundice, 
widespread subcutaneous hemorrhages, petechial and/or 
ecchymotic hemorrhages on the surface of other internal 
organs (including the serosa of the heart in experimentally 
infected puppies and kittens), and fluid in the body cavities. 
The peripheral lymph nodes and spleen are typically 
enlarged, congested and/or edematous to some degree, and 
may contain petechiae. A variable degree of inflammation 
or hemorrhagic enteritis can sometimes be found in the 
intestines of ruminants and experimentally infected puppies 
and kittens. Ruminants may have hemorrhages and edema 
in the abomasal folds, sometimes with blood in lumen of 
the intestine. The hemorrhagic syndrome reported in 7-11-
month-old, experimentally infected Yansaka sheep included 
unusual lesions of pulmonary edema/hemorrhage, and 
thrombosis in the heart, kidneys and brain. Aborted fetuses 
are often autolyzed. 
Diagnostic Tests  
Rift Valley fever can be diagnosed by detecting the 
virus in the blood of febrile animals, or the tissues of dead 
animals and aborted fetuses. Some recommended tissues for 
sampling include the liver (the major site of replication), 
spleen and brain, with some sources also recommending 
kidney and lymph nodes; however, the virus may also be 
found at other sites.  
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Several RT-PCR tests including loop-mediated 
isothermal amplification (LAMP) techniques can detect Rift 
Valley fever viral RNA. Virus isolation is also possible, but 
this virus is a hazard to laboratory personnel, and biosecure 
facilities are required. Rift Valley fever virus can be grown 
in numerous cell lines including baby hamster kidney cells, 
monkey kidney (Vero) cells, chicken embryo–related 
(CER) cells and AP61 mosquito cell lines, as well as in 
primary kidney or testis cultures from calves or lambs. 
Although animal inoculation is avoided whenever possible, 
hamsters, adult or suckling mice, embryonated chicken 
eggs or two-day-old lambs can also be used. Viral antigens 
can be detected by immunostaining or with enzyme 
immunoassays (ELISAs, lateral flow assays). Some 
ELISAs are commercially available. In addition, the high 
viral titers in some samples (e.g., tissues from aborted 
fetuses or blood) may allow a rapid diagnosis to be made 
with serological tests such as virus neutralization, using 
organ suspensions as the antigen. The latter test should be 
supplemented with other, more definitive, assays. 
ELISAs and virus neutralization can detect antibodies 
to RVF virus. Virus neutralization tests that require live 
virus are generally not recommended outside endemic 
regions or in laboratories not capable of biocontainment, 
but alternative neutralization tests that do not require highly 
virulent viruses are in development. Indirect 
immunofluorescence is used less frequently, while other 
serological assays employed in the past (hemagglutination 
inhibition, complement fixation, agar gel immunodiffusion) 
are generally no longer used. Cross-reactions with other 
phleboviruses can occur in serologic tests other than virus 
neutralization; however, the latter test has few or no issues 
with cross-reactivity.  
Treatment  
No specific treatment, other than supportive care, is 
available.  
Control 
Disease reporting 
A quick response is vital for containing outbreaks in 
RVF-free regions. Veterinarians who encounter or suspect 
this disease should follow their national and/or local 
guidelines for disease reporting. In the U.S., state or federal 
veterinary authorities should be informed immediately. 
Animals that may be infected with Rift Valley fever 
virus should also be reported immediately in endemic areas, 
to protect humans who may be exposed and aid in 
controlling the outbreak. In addition, the initial animal cases 
act as a warning that human outbreaks may be imminent, 
and reporting allows authorities to promptly issue public 
health messages and prevention advice. 
Prevention 
Vaccines are generally used to protect animals from 
Rift Valley fever in endemic regions. Vaccination of 
amplifying hosts may also reduce virus dissemination, and 
help protect people and other animals. Attenuated and 
inactivated Rift Valley fever vaccines are both available. 
An advantage to inactivated vaccines is their safety; 
however, they are less immunogenic than attenuated 
vaccines, and if quality control fails, an incompletely 
inactivated vaccine could introduce the virus to livestock. 
Attenuated RVF vaccines produce better immunity, but 
vaccine viruses might reassort with wild type RVF viruses, 
contributing to viral diversity. Attenuated RVF vaccines 
can also cause abortions and birth defects in pregnant 
animals. (A newer inactivated vaccine, called Clone 13, did 
not cause abortions or fetal deformities in pregnant ewes 
vaccinated at 15 days of gestation.) Vaccination campaigns 
conducted in resource-poor areas face additional challenges 
such as mechanical transmission from already infected 
animals when needles are reused. For this reason, some 
sources including the World Health Organization do not 
currently recommend that vaccination campaigns be 
initiated once an epidemic has begun. 
Because epidemics typically follow heavy rainfall, 
weather prediction models may give some advance warning 
when conditions are favorable for outbreaks. Sentinel herds 
have also been used as part of early warning systems in 
some areas. Movement bans or restrictions, and the closure 
of livestock markets during outbreaks, may help prevent 
virus transmission to unaffected regions. Larvicides are the 
most effective form of vector control, if mosquito breeding 
sites can be identified and are limited in size. However, 
breeding sites are usually extensive, making vector control 
impractical. 
Morbidity and Mortality  
Epidemics of Rift Valley fever tend to occur at 
intervals, when heavy rainfalls cause infected mosquito 
eggs to hatch and a susceptible animal population is 
present. In Africa, outbreaks typically occur in savannah 
regions every 3 to 15 years, and less frequently in some 
other areas. Low levels of infection can also be seen in 
livestock and wildlife during interepidemic periods. Some 
regions may mainly experience low-level virus activity 
during each rainy season, without explosive epidemics.  
The morbidity rate varies between outbreaks, and is 
influenced by factors such as pre-existing immunity, 
pregnancy status, and the age of the animals. In some cases, 
illnesses are widespread in herds throughout the country, 
and most of the animals in infected herds are affected. 
Among domesticated animals, infections seem to be most 
severe in sheep and goats. Abortion rates in sheep range 
from 5% to nearly 100%, but they are generally lower in 
cattle (e.g., < 10%). Widespread abortions have also been 
reported sometimes in camels; 10% of camels aborted in 
one outbreak. 
The case fatality rate can be very high in young animals, 
with fatalities decreasing in older age groups. The mortality 
rate may reach 70% to 100% in newborn lambs and kids, 
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while estimated mortality in calves, and older lambs and 
kids, varies from 10% to 70%. Overall, the mortality rate is 
estimated to be 10-30% in adult sheep and < 10% in adult 
cattle, but higher rates have been reported in some outbreaks 
or herds. Deaths are most common in pregnant ewes that 
abort. Some experiments suggest that there may be breed-
specific differences in the severity of clinical signs; however, 
naive sheep of breeds not indigenous to Africa (e.g., 
European breeds) do not necessarily become severely ill. 
Mortality rates were 81% in experimentally infected young 
kittens (≤ 2 weeks of age), and 50-100% in young puppies (≤ 
1 week of age), but no adult cats or dogs 2 weeks of age or 
older died. 
Infections in Humans  
Incubation Period  
In humans, the incubation period is estimated to be 3 to 
6 days. This is based on a limited number of cases, almost all 
acquired in the laboratory or by contact with the tissues of 
infected animals, rather than after exposure to mosquitoes. 
Clinical Signs  
Most people are infected subclinically with RVF virus 
or develop a mild to moderate, non-fatal, febrile flu-like 
illness with liver abnormalities The symptoms of 
uncomplicated infections are usually nonspecific and may 
include fever, headache, generalized weakness, dizziness, 
weight loss, myalgia and back pain. Some patients also 
have stiffness of the neck, photophobia and vomiting or 
diarrhea. Most people recover spontaneously within a week. 
A clinical syndrome that appears to be characteristic of 
severe Rift Valley fever was described in several patients 
during the 2006-2007 epidemic in Kenya, and included 
nonspecific signs of fever, malaise and headaches, together 
with arthralgia in the large joints (elbows, knees and 
shoulders), gastrointestinal signs (nausea, vomiting, mid-
epigastric pain), progressing to tender hepatomegaly, 
jaundice and delirium. Lymphadenopathy and diarrhea 
appeared to be absent in these patients. 
Complications including renal dysfunction, 
meningoencephalitis, ocular disease, or a hemorrhagic 
syndrome with liver involvement occur in a small 
percentage of patients. The hemorrhagic syndrome is the 
most serious form, and may be seen in up to 1% of patients, 
with symptoms usually developing 2-4 days after the initial 
signs. Jaundice may be the first indication of this syndrome, 
followed by signs such as hematemesis, melena, 
menorrhagia, a macular or purpuric rash, petechiae and 
bleeding from the gums. These patients often progress to 
frank hemorrhages, shock and death within 3-6 days. Acute 
kidney dysfunction is a new complication reported in severe 
cases during recent outbreaks, and can also lead to death. 
Whether the kidney dysfunction is caused directly by the 
virus or is a consequence of complications such as shock is 
still unclear. Survivors of this syndrome did not develop 
chronic kidney disease.  
Ocular disease and meningoencephalitis can be late 
complications of Rift Valley fever. The ocular form is 
estimated to occur in up to 2% of patients, typically begins 
1-3 weeks after the initial symptoms, and is characterized 
by retinal lesions and blurred vision. While ocular lesions 
disappear after 10-12 weeks in some patients, others 
experience some degree of permanent visual impairment, 
which may include blindness. Encephalitic signs are seen in 
less than 1%, and usually begin 1-4 weeks (but occasionally 
later) after the initial signs. The symptoms can include 
intense headache, memory loss, vertigo, hallucinations, 
confusion, disorientation, coma or seizures. Some patients 
have permanent neurological damage, which may be 
severe, but deaths are uncommon. 
Some authors indicate that increased mortality or 
abortions in pregnant women have not been seen during 
outbreaks. However there are at least two reports of 
maternal transmission to the fetus. One infant, whose 
mother was also ill with malaria, was born with a rash and 
jaundice. The infant in the other case died soon after birth. 
Diagnostic Tests  
Rift Valley fever virus can be detected in the blood, 
brain, liver or other tissues, but viremia usually occurs only 
during the first three days of fever. There are also reports of 
virus detection in other samples, such as throat swabs, 
cerebrospinal fluid, pericardial and peritoneal fluid. Tests to 
detect RVF virus in humans are similar to those used in 
animals, and can include PCR assays, virus isolation and 
various antigen detection assays. During some outbreaks, 
RT-PCR was able to identify people with high levels of 
viremia in the blood, who were more likely to progress to 
severe illness. ELISAs and other serological tests can detect 
specific IgM or rising titers.  
Treatment  
No specific treatment, other than supportive care, is 
available. Some animal studies have suggested that antiviral 
drugs or other therapies such as passive antibodies might be 
effective; however, these treatments have not been tested in 
humans. Most cases of Rift Valley fever are thought to be 
relatively mild, brief illnesses and resolve on their own.  
Prevention  
Public education about transmission methods can help 
reduce infections during outbreaks. Milk should be 
pasteurized or boiled, and all other animal tissues including 
blood and meat should be cooked, and not consumed raw. 
Home slaughter of livestock (a common practice in 
endemic areas) is not recommended during outbreaks.  
Barrier precautions (e.g., gloves and additional 
personal protective equipment) should be used whenever 
there is a possibility of contact with infectious tissues or 
blood or exposure to aerosolized virus. The specific 
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precautions can depend on the form of exposure, with 
necropsies considered high risk procedures. Diagnostic 
tissue samples should be processed by trained staff in 
appropriately equipped laboratories. An inactivated vaccine 
has been used in some at-risk individuals (e.g., laboratory 
workers), but has had limited availability, and is no longer 
manufactured by one former supplier. Although person-to-
person transmission has not been reported, there is a risk of 
transmission by contact with viruses in human blood and 
tissues. Standard (universal) precautions (e.g., barriers to 
prevent direct contact with blood and other potential 
sources of virus) have been recommended for healthcare 
workers who care for patients with confirmed or suspected 
Rift Valley fever. 
Mosquito repellents, long shirts and trousers, bednets, 
and other arthropod control measures should be used to 
prevent transmission by mosquitoes and other potential 
insect vectors. Outdoor activities should be avoided, if 
possible, during periods of peak mosquito activity. 
Morbidity and Mortality  
Humans are highly susceptible to Rift Valley fever. 
Specific risk factors include assisting at animal births, 
having contact with tissues (e.g., slaughtering or skinning 
an animal, preparing meat for cooking, handling abortion 
products, conducting necropsies), drinking raw 
(unpasteurized) milk, and sheltering animals within the 
home. Clinical cases are often seen in veterinarians, abattoir 
workers and others who work closely with blood and tissue 
samples from animals. Laboratory workers are also at risk. 
Human infections tend to occur mainly during Rift Valley 
fever epidemics in livestock, and are typically preceded by 
cases in animals; however, illnesses were first diagnosed in 
people during some outbreaks. Sporadic cases may also be 
seen during interepidemic periods.  
The vast majority of human infections appear to be 
asymptomatic or mild. However, the number of infections 
in some epidemics can be very large (e.g., possibly more 
than 180,000 infections in Kenya in 2006-2007), resulting 
in hundreds of serious cases and significant numbers of 
deaths. The overall case fatality rate for all patients with 
Rift Valley fever is estimated to be between 0.5% and 2%, 
but case fatality rates in hospitalized patients with more 
severe symptoms may be much higher (e.g., 31% of 747 
hospitalized patients in Sudan in 2006-2007). Case fatality 
rates up to 50% have been reported in the hemorrhagic 
syndrome, and the case fatality rate in people with acute 
renal dysfunction was 40% during an outbreak in Sudan. 
The fatality rate in serious cases may vary with the 
availability and quality of healthcare facilities in an area.  
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Fact Sheet 
http://www.who.int/mediacentre/factsheets/fs207/en/index.
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